cimetidine

(redirected from Tagamet HB 200)
Also found in: Thesaurus, Medical.
Related to Tagamet HB 200: cimetidine

ci·met·i·dine

 (sĭ-mĕt′ĭ-dēn′, -dīn′)
n.
A histamine receptor antagonist, C10H16N6S, that inhibits acid secretion in the stomach and is used to treat duodenal and gastric ulcers and gastroesophageal reflux disease.

[Alteration of cy(ano-) + met(hyl) + (guan)idine.]

cimetidine

(saɪˈmɛtɪdiːn)
n
(Pharmacology) a drug used to suppress the formation of acid by the stomach and so to encourage the healing of gastric and duodenal ulcers. Formula: C10H16-N6S

ci•met•i•dine

(saɪˈmɛt ɪˌdin)

n.
a substance, C10H16N6S, used for inhibiting gastric secretion in the treatment of duodenal ulcers.
[1975–80; probably ci-, resp. of cy(ano)-2 + met(hyl) + (guan)idine]
ThesaurusAntonymsRelated WordsSynonymsLegend:
Noun1.cimetidine - a drug (trade name Tagamet) used to treat peptic ulcers by decreasing the secretion of stomach acid
histamine blocker - a medicine used to treat the gastric effects of histamine in cases of peptic ulcers and gastritis and gastroesophageal reflux; works by blocking the effects of histamine on the receptor site known as H2
alkaliser, alkalizer, antacid, antiacid, gastric antacid - an agent that counteracts or neutralizes acidity (especially in the stomach)
References in periodicals archive ?
Just as the advent of such acid blockers as Pfizer Inc.'s Zantac 75, Johnson & Johnson Merck Consumer Pharmaceuticals' Pepcid AC and GlaxoSmithKline PLC's Tagamet HB 200 changed the way heartburn sufferers looked at antacids, Prilosec, the first product from a class of drugs known as proton pump inhibitors to be available without a prescription, has taken the category to a new level.
1999 Dollar sales 2000 1999 1999 Trade class (add 000) share share share Chain drug stores $64,820 35% N/A N/A Discount stores 44,448 24% N/A N/A Food/drug combination stores 42,596 23% N/A N/A Supermarkets 24,076 13% N/A N/A Independent drug stores 9,260 5% N/A N/A Best-sellers by dollar Sales [*] Market Dollar sales Unit sales Brand Manufacturer Share (add 000) add (000) Mylanta J&J-Merck 24.6% $45,592 9,106 Maalox Novartis 21.8% 40,309 7,748 Mylicon J&J-Merck 12.1% 22,441 2,432 Mylanta Supreme J&J-Merck 11.5% 21,337 4,679 Gaviscon SmithKline Beecham 5.8% 10,752 1,383 Beano Black Drug 1.9% 3,556 536 Riopan Plus Whitehall-Robins 1.4% 2,569 413 Tagamet HB 200 SmithKline Beecham 1.2% 2,193 249 Lactaid McNeil 1.0% 1,766 243 (*.)Private label products account for 14.
marketing the product under the Lamisil AT label; cimetidine suspension, an acid reducer, was transferred to O-T-C status, with SmithKline Beecham Consumer Healthcare making the product under the Tagamet HB 200 name; and Novartis' nicotine replacement transdermal patch (Habitrol) made the switch to nonprescription status.